AGP Company Limited:

Introducion:
AGP limited startes operation as an independent manufacturer in 1989. It manufacture
and market its own brand and also manufacturing and maketing with the international
reputed companies. Now a day it become the largest parmaceutical company in pakistan
it also provided tha large range of pharma products. The key motivating factor of this
company is to improve the quality life of a common man.

There operations include marketing, manufacturing and sale its product within and
across the country. It manufacturing plant is in Karachi, Pakistan.

History:
in 1989 AGP startes its comerical operations than in 1991 it enters into a joint venture
with Eli Lilly pakistan for its cephalosporins product rang. AGP signs an agreement with
UCB Belgium for manufacture and market its product in 1995. In 2003 it purchase Eli
Lilly for Ceclor, Keflex, Kefzol and Nebcin in pakistan. AGP sign agreement with OM
Switzerland in 2006 who is now Vifor to market and manufacture selected products. In
2007 AGP purchases UCB brand rightsfor Rigix in Pakistan. AGP enters into the supply
agreement with GSK Pakistan in 2009 for manufacturing of UCB products. In 2014 OSB
led consortium aquries AGP through an SPV Appollo pharma. In 2015 AGP(Pvt.)Ltd. and
AGP Healthcare(Pvt.)Ltd. merge into AGP Limited and it also sign an agreement with
Mylan for sales and marketing of their products in Pakistan. In 2018 AGP lists on Pakistan
Stock Exchange.

Vision:
Our vision is based on quality. We are dedicated to provide quality products and services
to our customers to meet their needs in ethical manner.We are responsible of giving
quality life to our customer.

Mission:
We create value for our customers,shareholders and employees, through effective use of
available resources by marketing and manufacturing healthcare products in an ethical
manner conforming to international quality standards.

Slogan:
We value life.

Hierarchy:

Chairman- Board of Director:

Mr. Tariq Moinuddin Khan he has 30 years pharmaceutical experience. He is also the
chairman of OBS Group, which is in the top ten pharmaceutical company in Pakistan. He
starts his career with the largest audit firm that is Richter Usher and Vineberg
Accountants, Montreal, Canada.

Managing Director & CEO:

Ms. Nusrat Munshi has 28 years experiece in banking pharma industry. She provide her
services as board of director in OBS pakistan(pvt.) ltd.
Chairman- Human Resource and Remuneration Committee:

Mr. Naved Abid Khan has 30 years experience over this industry. He provide his services
as Chairman and CEO in Sharmeen Khan Memorial Foundation. He also served his
services in Fyasal Bank Limited and Aroma Bank Pakistan Limited as the President and
CEO.

Chairman - Audit Committee:

Mr. Zafar Iqbal Sobani has 40 years experience of working in manufacturing sector.

Non-Executive Directors:

·0 Mr. Kamran Nishat has 34 years experience over there and he work as CEO of
Muller and Phipps Pakistan ltd.

·1 Mr. Mahmud Yar Hiraj has 15 years experience in corporate finance, investment
banking, principal investing, private equity and assest management.

·2 Mr. Muhammad Kamran Mirza has 11 years experience of financial markets he

focusrd on Sell-sideand Buy-side Investment Advisory.

Ferozsons Laboraties:
Introduction:
Ferozsons Laboraties Limited establish in 1956 as first Pharmaceutical manufacturing
company in Pakistan. thecompany listed in stock exchange Pakistan in 1960. The
company become the leadership brand in the field of gastroentology, hepatology,
cardiology and oncology.

Ferozsons is one of the biggest leading brand of Pakistan it maintain the agreement with
the international partners for seeling, co-manufacturing and dustribution of their
products. Ferozsons is only company in pakistan who provide biotech manufacturing
facility in the country.

The company also have exclusive partners for Gilead Science Inc. for their product range
related to HBV, HCV, and HIV, and also have hold in-country license for the
manufacturing of authorized generics of Gilead's products for HCV.

History:
In 1956 Ferozsons Laboraties Ltd. become one of the national company who establish
pharmaceutical maunfacturing plant in pakistan. In 1960 the company become listed in
Pakistan stock exchange with the authorized capital of PKR 10M and become the first
national companies to do so. In 1961 the company starts work on two new
maunfacturing facilities which deal in the production of glycerine and soap chemicals. In
1961-63 the starts exporting their products to the several international markets which
include Australia, Hong Kong, Jordan, Singapore, Turkey, UK and many more. In 1963
company launched a bath soap in the local market that become the one of the country's
iconic consumer brand. Company become the preferred supplier to international
organization and foriegn missions which includes United Nations, Government of USA
and British Crown Agents. In 1964-69 company collaborate with the leading
pharmaceutical companies around the world which includethe boot pure drug o.,
Chenmie Grubenthal Gmbh, Germany and many more. In 1988 company launched
Cimet(Cimetidine) that become the top-selling anti-ulcerants in the country. Ferozsons
signed agreement with yje Procter and Gable, Pakistan for the manufacturing of Vicks
Vaporub which is the famous brand of P&G. The company become thefirst
biopharmaceutcal manufacturing company in 2006. It acquries the distribution rights of
Boston Scientific, inc. USA which is the world's largest manufacturer of medical device in
2008. The company made partnership with Gilead Science, inc. sovaldi,the miracle of
Hepatitis C virus cure in the country, due to this Pakistan become the first country who
implement and accress program under which thousand of patient receive the medicien.
In 2016 compang signed agreeme nt wthe GE healthcare and become its partner to sell
and market the market devices in Pakistan market. In 2017 company made patnership
with PanTheryx Inc. USA to exclusively market breakthrough nutitional products for
childhood diarrhea, DiaResQ that is featured in the innovations 2030 countdown report
issused jointly by PATH, USAID and NORAD.

Vision:
"We will strive to attain market leadership by putting patients first and seeing everyday
as a new opportunity to earn trust and credibility."

Mission:
"We aim to improve the quality of life by providing innovation healthcare solutions,
ensuring patient access to treatment and cure."

Hierarchy: